drugset / Trial / NCT06653296
A Dose-Response Safety Study of ENX-102 in Patients With GAD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD
Timeline
- Start
- 2024-12-09
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENX-102 | Unknown | 0.5 mg | Oral |
| Subject | ENX-102 | Unknown | 1 mg | Oral |
| Subject | ENX-102 | Unknown | 3 mg | Oral |